Danaher Corporation (DHR)
Danaher: High Capex And Low Debt Despite Trump Legislation
The company has achieved returns on equity above 7.8% since 2019. Additionally, it reduced its liabilities-to-assets ratio to 35.72% this quarter, indicating a low risk of bankruptcy. Danaher expects an excellent growth outlook in the upcoming years, due to the significant investment that the biopharma industry has dedicated to developing new medical therapies. Between 2017 and 2024, Danaher invested 25.81% of its revenues to expand its operations, which has contributed to the growth rate of its revenues.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Here's Why Investors Should Consider Retaining Danaher Stock Now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team and I'm excited to host our next session.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered better-than-expected Q1 2025 results, driven by strong performance in biotechnology and molecular diagnostics, despite maintaining conservative guidance. DHR has repurchased 4.5 million shares this year, with 12 million more to go, aligning with their strategy of benefiting from a lower stock price.
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2025 Earnings Results Conference Call.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
